A Trial of SHR7280 in Healthy Subjects
The study is being conducted to evaluate the effect of high-fat meal on pharmacokinetics of SHR7280 after oral administration and the effect of SHR7280 on QT interval at low and high doses in healthy Chinese volunteers.
Endometriosis|Uterine Fibroids|Assisted Reproduction
DRUG: SHR7280 Tablet|DRUG: SHR7280 Placebo Tablet
Peak concentration (Cmax), Day 1 to Day 8.|Area under the plasma concentration-time curve from time 0 to the last quantifiable timepoint (AUC0-t), Day 1 to Day 8.|Area under the plasma concentration-time curve from time 0 to infinity (AUC0-âˆž), Day 1 to Day 8.
Time to peak concentration (Tmax), Day 1 to Day 8.|Elimination half-life (t1/2), Day 1 to Day 8.|Adverse events (AEs), Day 1 to Day 15.
The study is being conducted to evaluate the effect of high-fat meal on pharmacokinetics of SHR7280 after oral administration and the effect of SHR7280 on QT interval at low and high doses in healthy Chinese volunteers.